In 2024 Blue Cross Blue Shield of Michigan informed members and physicians about a change in coverage for GLP-1s.On the surface, GLP-1s promise weight loss, lower blood pressure and a reduced risk of heart and kidney disease, according to the Cleveland Clinic
It does not replace the official medication guide, patient information leaflet, counseling from your pharmacist, or medical advice from your prescriber
Through Q3, Hims & Hers' subscribers grew to more than 2.5 million, up 21% year over year
Weight loss for both the pill and injection may increase when you get closer to your full maintenance dose, usually after a few months
Several brands are incoming, which includes Sun Pharmaceuticals Sematrinity and Noveltreat (priced between 2,690 and 7,490, depending on dose)
Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite and body weight, while tesamorelin is a growth hormone-releasing hormone analogue that stimulates pituitary GH release to reduce visceral fat, primarily in HIV-positive patients with lipodystrophy